Illumina Launches TruSight HLA Solution
March 04 2015 - 6:30AM
Business Wire
New Research Solution Provides Efficient,
Highly Accurate Sequencing of Human Leukocyte Antigen (HLA) Region
of the Genome
Illumina, Inc. (NASDAQ:ILMN) today announced the launch of
TruSight® HLA, a complete, end-to-end solution that produces a
comprehensive view of the HLA region by sequencing 11 HLA genes for
accurate HLA typing across thousands of known and novel HLA
alleles. Leveraging the MiSeq® Sequencing System, the kit includes
the TruSight HLA Sequencing Panel, a single assay for ultra-high
resolution analysis of all the key genes within the major
histocompatibility complex (MHC), reagents for preparing and
sequencing DNA libraries, and optimized data analysis with software
from Conexio Genomics.
“Next-generation sequencing has great potential for HLA typing,
but it has not been widely adopted beyond a few specialized
laboratories,” said Matthew Anderson, M.D., Ph.D., Medical
Director, BloodCenter of Wisconsin. “Our evaluation of TruSight HLA
demonstrates the benefits that NGS technology can provide with a
single, accurate, multi-locus assay that provides the resolution
required to make confident HLA calls. TruSight HLA will enable more
laboratories to harness the power of next-generation sequencing for
HLA typing.”
HLA plays a large role in the body’s ability to recognize
invasive cells and mount an immune response thus helping to fight
disease and maintain overall health. This region of the genome is
notoriously challenging to study due to high levels of sequence
homology and dense variability. Currently the standard typing
protocol requires 10 to 20 assays in two or three sequential rounds
of testing to generate a high confidence HLA type with results
based on about 6,500 base pairs of DNA sequence. TruSight HLA uses
a single assay and generates results based on 65,000 base pairs, a
ten-fold increase in sequence coverage, which significantly
streamlines the workflow while greatly expanding the capacity to
discover novel alleles.
TruSight HLA leverages Illumina sequencing by synthesis
chemistry, the most trusted NGS technology. HLA typing researchers
can use the solution to replace the multiple rounds of testing and
the dozens of assays currently necessary to resolve ambiguous
results. Through a streamlined workflow and multiplexed samples,
this single assay and tightly integrated software enable labs to
reduce hands-on time, decrease costs, improve productivity, and
increase confidence in the results, while generating unambiguous,
phase-resolved HLA typing results in less than four days.
“The HLA region of the genome plays a critical role in
autoimmune disorders, cancer, transplant rejection, and drug
sensitivity, but conventional technologies cannot efficiently
sequence the region,” said Kirk Malloy, Senior Vice President and
General Manager of Illumina’s Life Science Business. “By providing
researchers with a reliable, faster, easier, more comprehensive
method of HLA sequencing, TruSight HLA is one of many examples of
how next-generation sequencing technologies from Illumina can be
applied to new markets where unlocking the power of the human
genome holds great potential to make a positive difference in
people’s lives.”
The TruSight HLA is now shipping. For more information, visit
www.illumina.com/HLAseq.
About Illumina
Illumina is transforming human health as the global leader in
sequencing and array-based technologies. The company serves
customers in a broad range of markets, enabling the adoption of
genomic solutions in research and clinical settings. To learn how
Illumina is unlocking the power of the genome,
visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release may contain forward looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements include challenges inherent in developing,
manufacturing, and launching new products and services and the
other factors that are detailed in our filings with the Securities
and Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Jennifer Temple,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024